We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Subscribe To Our Newsletter & Stay Updated
